Cisplatin liposomes cut side effects

A pH-sensitive form of liposomal cisplatin could mean better treatment of peritoneal carcinomatosis (where cancers metastasize throughout the lining of the abdomen), with fewer side effects. The liposomes have been designed by Brazilian researchers to release the drug near the tumor, and tests in mice showed better effects against the cancer, with longer survival, as well as fewer side effects on the kidney and bone marrow. Further studies are under way. The results were published in Experimental Biology and Medicine. Press release  | Abstract

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.